Matinas Biopharma (MTNB) News Today $0.55 -0.02 (-3.81%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Matinas BioPharma Faces Uncertain Future After Halting MAT2203 DevelopmentNovember 16, 2024 | markets.businessinsider.comMatinas BioPharma downgraded to Neutral from Buy at Alliance Global PartnersNovember 2, 2024 | markets.businessinsider.comMaxim Group Downgrades Matinas BioPharma Holdings (MTNB)November 1, 2024 | msn.comMatinas BioPharma downgraded to Hold from Buy at MaximOctober 31, 2024 | markets.businessinsider.comMatinas BioPharma says MAT2203 partnership negotiations terminatedOctober 31, 2024 | markets.businessinsider.comMatinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionOctober 31, 2024 | globenewswire.comHighbridge Capital Management's Strategic Acquisition in Matinas BioPharmaOctober 25, 2024 | finance.yahoo.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTowercrest Capital Management Acquires New Position in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB)Towercrest Capital Management bought a new position in shares of Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,886,715 sharesSeptember 8, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Down to $3.72Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Down to $3.72September 5, 2024 | marketbeat.comMatinas BioPharma (NYSEAMERICAN:MTNB) Reaches New 12-Month Low at $3.77Matinas BioPharma (NYSEAMERICAN:MTNB) Sets New 52-Week Low at $3.77September 4, 2024 | marketbeat.comMatinas BioPharma Hldgs (AMEX:MTNB) Stock, Insider Trading ActivitySeptember 3, 2024 | benzinga.comMatinas BioPharma (NYSEAMERICAN:MTNB) Trading 4,230.1% Higher Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Up 4,230.1%September 3, 2024 | marketbeat.comMatinas BioPharma enacts reverse stock splitAugust 30, 2024 | uk.investing.comMatinas BioPharma (NYSEAMERICAN:MTNB) Hits New 1-Year High at $4.67Matinas BioPharma (NYSEAMERICAN:MTNB) Hits New 52-Week High at $4.67August 29, 2024 | marketbeat.comMatinas BioPharma Holdings Inc (6LJ.DU)August 25, 2024 | nz.finance.yahoo.comBuy Rating Affirmed: Matinas BioPharma’s Solid Financials and Promising Drug DevelopmentAugust 17, 2024 | markets.businessinsider.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 15, 2024 | finanznachrichten.deMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q2 2024August 14, 2024 | markets.businessinsider.comMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | globenewswire.comMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024August 7, 2024 | globenewswire.comMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramJune 24, 2024 | globenewswire.comMatinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.June 13, 2024 | globenewswire.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 16, 2024 | investorplace.comNew In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | finance.yahoo.comNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024May 16, 2024 | globenewswire.comBuy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal CandidateMay 11, 2024 | markets.businessinsider.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Matinas BioPharma Holdings Inc Earnings CallMay 10, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 10, 2024 | finanznachrichten.deMTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024May 9, 2024 | investorplace.comMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 9, 2024 | globenewswire.comMatinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingMay 7, 2024 | finance.yahoo.comMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024May 2, 2024 | globenewswire.comOral fungal infection treatment shows promise in preclinical trialsApril 30, 2024 | msn.comIn Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyApril 30, 2024 | finance.yahoo.comMatinas Declines on Public OfferingApril 3, 2024 | msn.comMatinas BioPharma Prices $10 Million Registered Direct OfferingApril 3, 2024 | globenewswire.comMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call TranscriptApril 1, 2024 | finance.yahoo.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 28, 2024 | finanznachrichten.deMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings ResultsMatinas BioPharma (NYSEAMERICAN:MTNB - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter.March 28, 2024 | marketbeat.comQ4 2023 Matinas BioPharma Holdings Inc Earnings CallMarch 28, 2024 | finance.yahoo.comMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023March 27, 2024 | investorplace.comMatinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateMarch 27, 2024 | globenewswire.comMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 25, 2024 | finanznachrichten.deMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationMarch 25, 2024 | globenewswire.comWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?March 22, 2024 | finance.yahoo.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | finance.yahoo.comThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseMarch 22, 2024 | globenewswire.com Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. MTNB Media Mentions By Week MTNB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼0.000.60▲Average Medical News Sentiment MTNB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼01▲MTNB Articles Average Week Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNSE News TSBX News PHXM News JAGX News INDP News CLRB News MYNZ News CYCN News EGRX News BCDA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:MTNB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
